235420-68-5

Usage

Uses

Used in Pharmaceutical Compounds Synthesis:
4-Allylamino piperidine-1-carboxylic acid tert-butyl ester is utilized as an intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new therapeutic agents. Its unique structure and reactivity make it a versatile building block in medicinal chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Allylamino piperidine-1-carboxylic acid tert-butyl ester is employed as a key component in the design and synthesis of novel drug candidates. Its presence in the molecular structure can influence the pharmacological properties and therapeutic potential of the resulting compounds.
Used in Drug Development:
4-Allylamino piperidine-1-carboxylic acid tert-butyl ester plays a crucial role in drug development, where it is used to create new molecules with potential therapeutic applications. Its versatility and reactivity in chemical reactions facilitate the exploration of various chemical pathways and the discovery of innovative drug candidates.
Used in Organic Synthesis:
Beyond its applications in pharmaceuticals, 4-Allylamino piperidine-1-carboxylic acid tert-butyl ester also has potential uses in organic synthesis. Its unique structure allows it to participate in a range of chemical reactions, contributing to the synthesis of various organic molecules for different applications.
Used in Chemical Research:
In the realm of chemical research, 4-Allylamino piperidine-1-carboxylic acid tert-butyl ester serves as a subject of study, enabling scientists to explore its chemical properties, reactivity, and potential applications in various chemical processes. This research can lead to a deeper understanding of its role in chemical reactions and the development of new synthetic methods.

InChI:InChI=1/C13H24N2O2/c1-5-8-14-11-6-9-15(10-7-11)12(16)17-13(2,3)4/h5,11,14H,1,6-10H2,2-4H3

Upstream product

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 106-95-6 allyl bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 107-11-9 1-amino-2-propene 

Downstream Products

• 235420-67-4 1-(tert-butoxycarbonyl)-4-(N-(4-nitrobenzyloxycarbonyl)-N-(allyl)amino)piperidine 
• 1259908-68-3 C₂₂H₂₉F₃N₂O₅ 
• 1259908-62-7 C₂₂H₃₂N₂O₆S 
• 1259908-61-6 C₂₃H₃₂N₂O₆ 
• 1259908-65-0 C₂₂H₂₉N₃O₄ 
• 1259909-00-6 C₂₃H₃₃N₃O₅ 
• 1259909-02-8 C₂₂H₃₂N₄O₄ 
• 1292801-57-0 C₂₂H₂₉F₃N₂O₃ 
• 1292801-87-6 C₂₂H₃₂N₂O₅S 
• 1292801-89-8 C₂₂H₂₉F₃N₂O₄ 
• 1259908-99-0 C₂₁H₃₁N₃O₅S 
• 1259908-93-4 C₂₁H₂₈N₄O₃ 
• 1292801-91-2 C₂₂H₃₁N₃O₄ 
• 1259908-88-7 C₂₀H₂₈FN₃O₃ 

Relevant academic research and scientific papers

Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B

Due to increasing emergence of bacterial resistance, compounds with new mechanisms of action are of paramount importance. One of modestly researched therapeutic targets in the field of antibacterial discovery is DNA gyrase B. In the present work we synthesized a focused library of potential DNA gyrase B inhibitors composed of two key pharmacophoric moieties linked by three types of sp3-rich linkers to obtain three structural classes of compounds. Using molecular docking, molecular dynamics and analysis of conserved waters in the binding site, we identified a favourable binding mode for piperidin-4-yl and 4-cyclohexyl pyrrole-2-carboxamides while predicting unfavourable interactions with the active site for piperazine pyrrole-2-carboxamides. Biological evaluation of prepared compounds on isolated enzyme DNA gyrase B confirmed our predictions and afforded multiple moderately potent inhibitors of DNA gyrase B. Namely trans-4-(4,5-dibromo-1H-pyrrole-2-carboxamide)cyclohexyl)glycine and 4-(4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)piperidin-1-yl)-4-oxobutanoic acid with an IC50value of 16 and 0.5?μM respectively.

Discovery of N-benzyl-N′-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): Optimization of the amine portion

Several series of carbamate, urea and carboxamide-based CCR5 antagonists have been discovered via optimizations at the amine portion of lead compound 2. All compounds were evaluated for their antiviral activities. Lead urea 29 showed good pharmacokinetic properties, justifying further development of this series.

Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents

Modification of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists revealed that introducing a fluoro group at the 3-position of the 3-phenyl group to reduce metabolism did not adversely affect the high potency against HIV infection, and that replacing the piperidine ring with a tropane ring could deliver the most potent anti-HIV agents. Stereochemistry of the substituted tropane ring is essential for maintaining the potent anti-HIV activity because only exo-isomers displayed subnanomolar whole cell activity.

PYROLLIDINE-BASED COMPOUNDS

The present invention discloses the compounds of formula ( I ) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.

PYROLLIDINE-BASED COMPOUNDS

A compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes

(2S)-2-(3-Chlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro (2,3-dihydrobenzthiophene-3,4′-piperidin-1′-yl)]butane S-oxide (1b) has been identified as a potent CCR5 antagonist having an IC50 = 10 nM. Herein, structure-activity relationship studies of non-spiro piperidines are described, which led to the discovery of 4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidine derivatives (3-5) as potent CCR5 antagonists.

Cyclic amine modulators of chemokine receptor activity

The present invention is directed to cyclic amines of the formula I: (wherein R1, R2, R3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.